{"id":"placebo-matched-with-pregabalin","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Dizziness"},{"rate":"15–25%","effect":"Somnolence"},{"rate":"5–10%","effect":"Peripheral edema"},{"rate":"5–10%","effect":"Weight gain"},{"rate":"5–10%","effect":"Blurred vision"},{"rate":"5–10%","effect":"Ataxia"}]},"_chembl":{"chemblId":"CHEMBL1059","moleculeType":"Small molecule","molecularWeight":"159.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pregabalin is a gabapentinoid that decreases calcium influx into nerve terminals by binding to the alpha-2-delta-1 subunit of presynaptic voltage-gated calcium channels. This reduces the release of glutamate, noradrenaline, and substance P, thereby dampening neuronal excitability. The mechanism underlies its efficacy in neuropathic pain, seizures, and anxiety disorders.","oneSentence":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:53.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain"},{"name":"Partial-onset seizures"},{"name":"Generalized anxiety disorder"},{"name":"Postherpetic neuralgia"}]},"trialDetails":[{"nctId":"NCT07495943","phase":"NA","title":"Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia","status":"NOT_YET_RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2026-05-04","conditions":"Fibromyalgia Syndrome, Fibromyalgia","enrollment":200},{"nctId":"NCT06619860","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-10-18","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":300},{"nctId":"NCT06628908","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-10-01","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":1100},{"nctId":"NCT07000201","phase":"NA","title":"Preoperative Pregabalin vs Gabapentin in Elderly Undergoing Surgry,Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-09-15","conditions":"Anxiety, Anxiety Disorder (Panic Disorder or GAD)","enrollment":84},{"nctId":"NCT05660538","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-20","conditions":"Diabetic Peripheral Neuropathy","enrollment":194},{"nctId":"NCT06221241","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-03-25","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":220},{"nctId":"NCT01939366","phase":"PHASE2","title":"Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-09-27","conditions":"Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus","enrollment":699},{"nctId":"NCT00468845","phase":"PHASE3","title":"Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-06","conditions":"Pain, Postoperative","enrollment":501},{"nctId":"NCT00368745","phase":"PHASE3","title":"Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-09","conditions":"Generalized Anxiety Disorder","enrollment":108},{"nctId":"NCT00313820","phase":"PHASE4","title":"Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-08","conditions":"Central Neuropathic Pain","enrollment":220},{"nctId":"NCT01020474","phase":"PHASE4","title":"Adolescent Fibromyalgia Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-05","conditions":"Fibromyalgia","enrollment":107},{"nctId":"NCT01455415","phase":"PHASE3","title":"Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-12","conditions":"Painful Diabetic Peripheral Neuropathy","enrollment":306},{"nctId":"NCT01387607","phase":"PHASE3","title":"A Study For Pregabalin In Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2012-02-06","conditions":"Fibromyalgia","enrollment":343},{"nctId":"NCT01474772","phase":"PHASE3","title":"Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-10","conditions":"Diabetic Peripheral Neuropathy","enrollment":217},{"nctId":"NCT01332149","phase":"PHASE3","title":"Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-07","conditions":"Diabetic Neuropathy, Painful","enrollment":626},{"nctId":"NCT01262677","phase":"PHASE3","title":"Once-A-Day Pregabalin For Partial Seizures","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-02-17","conditions":"Partial Seizures, Epilepsies, Partial","enrollment":325},{"nctId":"NCT00645398","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-09","conditions":"Fibromyalgia","enrollment":751},{"nctId":"NCT01271933","phase":"PHASE3","title":"Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Fibromyalgia","enrollment":441},{"nctId":"NCT01496365","phase":"PHASE2","title":"Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-11-28","conditions":"Diabetic Peripheral Neuropathy","enrollment":452},{"nctId":"NCT02187471","phase":"PHASE3","title":"Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-01-16","conditions":"Pain Associated With Fibromyalgia","enrollment":1301},{"nctId":"NCT02187159","phase":"PHASE3","title":"Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-11","conditions":"Pain Associated With Fibromyalgia","enrollment":1270},{"nctId":"NCT02146430","phase":"PHASE3","title":"Treatment of Pain Associated With Fibromyalgia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-10-27","conditions":"Pain Associated With Fibromyalgia","enrollment":1293},{"nctId":"NCT04499209","phase":"PHASE1","title":"Pharmacokinetics Study of XG005 Capsule","status":"COMPLETED","sponsor":"Xgene Pharmaceutical Group","startDate":"2017-10-16","conditions":"Pain","enrollment":50},{"nctId":"NCT03179345","phase":"PHASE4","title":"Simulated Driving Performance, Daytime Sedation and Cognition in Healthy Volunteers Taking Gralise, Neurontin or Lyrica","status":"COMPLETED","sponsor":"Depomed","startDate":"2015-09-24","conditions":"Healthy","enrollment":32},{"nctId":"NCT01485094","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain","status":"TERMINATED","sponsor":"Grünenthal GmbH","startDate":"2012-02","conditions":"Neuralgia","enrollment":114},{"nctId":"NCT02037165","phase":"PHASE1","title":"Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01-21","conditions":"Healthy","enrollment":25},{"nctId":"NCT02782169","phase":"PHASE4","title":"Prophylactic Pregabalin to Decrease Pain During Medical Abortion","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2015-06","conditions":"Acute Pain","enrollment":110},{"nctId":"NCT02215252","phase":"PHASE2","title":"A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-11-10","conditions":"Diabetic Neuropathy, Painful","enrollment":141},{"nctId":"NCT01928381","phase":"PHASE2","title":"Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-11","conditions":"Diabetic Neuropathy, Painful; Diabetic Neuropathies","enrollment":150},{"nctId":"NCT01314222","phase":"PHASE2","title":"Diabetic Peripheral Neuropathic Pain (DPNP)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":178},{"nctId":"NCT01688947","phase":"PHASE2","title":"Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2012-09","conditions":"Postherpetic Neuralgia, Pain","enrollment":105},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98},{"nctId":"NCT00643136","phase":"PHASE3","title":"A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Sleep Deprivation, Epilepsies, Partial","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matched with pregabalin","genericName":"Placebo matched with pregabalin","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain, Partial-onset seizures, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}